Current prescribing for pyoderma gangrenosum in the UK and access to biologic medications: results from a UK Dermatology Clinical Trials Network survey of dermatologists

• Published in: Clinical and experimental dermatology 2024-09, Vol.49 (10), p.1213-1216
• Main Authors: Jenkins, Myfanwy, Watson, Nicola, McPhee, Margaret, Levell, Nick J, Arden-Jones, Mike, D Ormerod, Anthony, Hampton, Philip J
• Format: Article
• Language: English
• Subjects: Biological Products - therapeutic use; Dermatologists - statistics & numerical data; Dermatology - statistics & numerical data; Health Services Accessibility - statistics & numerical data; Humans; Practice Patterns, Physicians' - statistics & numerical data; Prednisolone - therapeutic use; Pyoderma Gangrenosum - drug therapy; Surveys and Questionnaires; United Kingdom
• ISSN: 0307-6938; 1365-2230; 1365-2230
• DOI: 10.1093/ced/llae153

Pyoderma gangrenosum (PG) is an ulcerative inflammatory disorder affecting the lower legs in 80% of patients. The use of biologic medications to treat PG is increasing, although there is a limited evidence base to guide treatment choices. In some health systems, such as the UK National Health Service, limitations are placed on biologic prescribing for PG, leading to wide variations in prescribing. A survey of mainly UK clinicians showed that prednisolone remains the first-line treatment for PG (90%, 34/38). Biologics have been used by 66% (25/38) of clinicians as second-line therapy, but 19% (7/38) have had prescribing requests declined. Further research is needed to determine optimal treatment strategies for PG.